References
- American Cancer SocietyCancer facts and figures 2013 Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index Updated 2013Accessed October 8, 2013
- MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc200883558459418452692
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®)Non-small cell lung cancer Version 22013 Available from: http://www.nccn.com. Updated 2013Accessed October 8, 2013
- JännePAEngelmanJAJohnsonBEEpidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biologyJ Clin Oncol200523143227323415886310
- CepedaVFuertesMACastillaJAlonsoCQuevedoCPérezJMBiochemical mechanisms of cisplatin cytotoxicityAnticancer Agents Med Chem20077131817266502
- KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
- PaezJGJännePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
- ShigematsuHLinLTakahashiTClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst200597533934615741570
- ThunnissenEBubendorfLDietelMEML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsVirchows Arch2012461324525722825000
- GarbeCEigentlerTKKeilholzUHauschildAKirkwoodJMSystematic review of medical treatment in melanoma: current status and future prospectsOncologist201116152421212434
- PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
- TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
- WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
- WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
- SchreiberRDOldLJSmythMJCancer immunoediting: integrating immunity’s roles in cancer suppression and promotionScience201133160241565157021436444
- GrulichAEvan LeeuwenMTFalsterMOVajdicCMIncidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysisLancet20073709581596717617273
- FifeBTBluestoneJAControl of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathwaysImmunol Rev200822416618218759926
- BabaTHanagiriTIchikiYLack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/BCancer Sci200798111795180217725806
- FukuyamaTIchikiYYamadaSCytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/ immunological responses both in vivo and in vitroCancer Sci20079871048105417511773
- JadusMRNatividadJMaiALung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionClin Dev Immunol2012201216072422899945
- NiehansGABrunnerTFrizelleSPHuman lung carcinomas express Fas ligandCancer Res1997576100710129067260
- PetersenRPCampaMJSperlazzaJTumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patientsCancer2006107122866287217099880
- ShimizuKNakataMHiramiYYukawaTMaedaATanemotoKTumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancerJ Thorac Oncol20105558559020234320
- Yervoy®(ipilimumab) [package insert]Princeton, NJ, USABristol-Myers Squibb Company2013
- HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
- Provenge®(ipilimumab) [package insert]Seattle, WA, USADendreon Corporation2011
- KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
- Al-ShibliKIDonnemTAl-SaadSPerssonMBremnesRMBusundLTPrognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancerClin Cancer Res200814165220522718698040
- Dieu-NosjeanMCAntoineMDanelCLong-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structuresJ Clin Oncol200826274410441718802153
- HiraokaKMiyamotoMChoYConcurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinomaBr J Cancer200694227528016421594
- ZhuangXXiaXWangCA high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosisAppl Immunohistochem Mol Morphol2010181242819713832
- TakanamiITakeuchiKGigaMThe prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinomaJ Thorac Cardiovasc Surg200112161058106311385371
- VillegasFRCocaSVillarrubiaVGPrognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancerLung Cancer2002351232811750709
- DasanuCASethiNAhmedNImmune alterations and emerging immunotherapeutic approaches in lung cancerExpert Opin Biol Ther201212792393722559147
- PlatonovaSCherfils-ViciniJDamotteDProfound coordinated alterations of intratumoral natural killer cell phenotype and function in lung carcinomaCancer Res201171165412542221708957
- SchneiderTHoffmannHDienemannHNon-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3J Thorac Oncol2011671162116821597388
- SchneiderTKimpflerSWarthAFoxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinomaJ Thorac Oncol20116343243821258248
- WangRLuMZhangJIncreased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancerJ Exp Clin Cancer Res2011306221595995
- ZeniEMazzettiLMiottoDMacrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancerEur Respir J200730462763217537769
- HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
- Lyseng-WilliamsonKAFentonCDocetaxel: a review of its use in metastatic breast cancerDrugs200565172513253116296875
- Xalkori®(crizotinib) [package insert]New York, NY, USAPfizer2013
- PallisAGFennellDASzutowiczELeighlNBGreillierLDziadziuszkoRBiomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancerBr J Cancer201110511821654681
- ShepherdFARodriguesPJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
- BangYJThe potential for crizotinib in non-small cell lung cancer: a perspective reviewTher Adv Med Oncol20113627929122084642
- SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
- SienelWVarwerkCLinderAMelanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center studyEur J Cardiothorac Surg200425113113414690745
- VansteenkisteJFZielinskiMLinderAAdjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study resultsJ Clin Oncol201343 Abstr 7103
- GlaxoSmithKlineGSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer Available from: http://clinicaltrials.gov/show/NCT00480025. NLM identifier NCT00480025Accessed December 11, 2013
- ReckMVansteenkisteJBrahmerJRTargeting the immune system for management of NSCLC: the revival?Curr Respir Care Rep2013212239
- ButtsCMurrayNMaksymiukARandomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancerJ Clin Oncol200523276674668116170175
- EMDSeronoCancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) Available from: http://clinicaltrials.gov/ct2/show/NCT00409188 NLM identifier: NCT00409188Accessed December 11, 2013
- Merck KGaACancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE) Available from: http://clinicaltrials.gov/ct2/show/NCT01015443 NLM identifier: NCT01015443Accessed December 11, 2013
- QuoixERamlauRWesteelVTherapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trialLancet Oncol201112121125113322019520
- TransgenePhase IIB/III of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME) Available from: http://clinicaltrials.gov/show/NCT01383148 NLM identifier: NCT01383148Accessed December 11, 2013
- NemunaitisJDillmanROSchwarzenbergerPOPhase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancerJ Clin Oncol200624294721473016966690
- NovaRx CorporationPhase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP) Available from: http://clinicaltrials.gov/show/NCT00676507 NLM identifier: NCT00676507Accessed December 11, 2013
- Neninger VinagerasEde la TorreAOsorio RodríguezMPhase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancerJ Clin Oncol20082691452145818349395
- Bioven EuropeA Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients (NSCLC) Available from: http://clinicaltrials.gov/show/NCT01444118 NLM identifier: NCT01444118Accessed December 11, 2013
- MargolinKAWongSLPenrodJREffectiveness and safety of first-line ipilimumab 3 mg/kg therapy for advanced melanoma: evidence from a US multisite retrospective chart reviewPoster 3742 presented at the European Cancer CongressSeptember 27 to October 1, 2013Amsterdam, The Netherlands
- PattDJudayTPenrodJRChenCWongSLA community-based, real-world, study of treatment-naïve advanced melanoma (AM) patients treated with 3 mg/kg ipilimumab (IPI) in the United StatesPoster 3751 presented at the European Cancer CongressSeptember 27 to October 1, 2013Amsterdam, The Netherlands
- LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
- Bristol-Myers SquibbTrial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin Available from: http://clinicaltrials.gov/show/NCT01285609 NLM identifier: NCT01285609Accessed December 11, 2013
- HamidOCarvajalRDAnti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapyExpert Opin Biol Ther201313684786123421934
- BrahmerJRHornLAntoniaSJNivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trialAbstract MO18.03 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung CancerOctober 27–30, 2013Sydney, Australia
- Bristol-Myers SquibbStudy of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) Available from: http://clinicaltrials.gov/show/NCT01642004 NLM identifier: NCT01642004Accessed December 11, 2013
- Bristol-Myers SquibbStudy of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate 057) Available from: http://clinicaltrials.gov/show/NCT01673867 NLM identifier: NCT01673867Accessed December 11, 2013
- Bristol-Myers SquibbStudy of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens (CheckMate 063) Available from: http://clinicaltrials.gov/show/NCT01721759 NLM identifier: NCT01721759Accessed December 11, 2013
- Bristol-Myers SquibbA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors Available from: http://clinicaltrials.gov/show/NCT01928394 NLM identifier: NCT01928394Accessed December 11, 2013
- Sidney Kimmel Comprehensive Cancer CenterPhase II Anti-PD1 Epigenetic Priming Study in NSCLC. (NA_00084192) Available from: http://clinicaltrials.gov/show/NCT01928576 NLM identifier: NCT01928576Accessed December 11, 2013
- Bristol-Myers SquibbStudy of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/ Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Available from: http://clinicaltrials.gov/show/NCT01454102 NLM identifier: NCT01454102Accessed December 11, 2013
- HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
- GaronEBBalmanoukianAHamidOPreliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC)Abstract MO18.02 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung CancerOctober 27–30, 2013Sydney, Australia
- MerckStudy of Two Doses of MK-3475 Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010) Available from: http://clinicaltrials.gov/show/NCT01905657 NLM identifier: NCT01905657Accessed December 11, 2013
- BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
- HornLHerbstRSSpigelDRAn analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1)Abstract MO18.01 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung CancerOctober 27–30, 2013Sydney, Australia
- GenentechA Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Available from: http://clinicaltrials.gov/show/NCT01846416 NLM identifier: NCT01846416Accessed December 11, 2013
- Hoffmann-La RocheA Study of MPDL3280A Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure Available from: http://clinicaltrials.gov/show/NCT01903993 NLM identifier: NCT01903993Accessed December 11, 2013
- Bristol-Myers SquibbStudy of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/ Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Available from: http://clinicaltrials.gov/show/NCT01454102 NLM identifier: NCT01454102Accessed December 11, 2013
- Bristol-Myers SquibbSafety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors Available from: http://clinicaltrials.gov/show/NCT01629758 NLM identifier: NCT01629758Accessed December 11, 2013
- Bristol-Myers SquibbA Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors Available from: http://clinicaltrials.gov/show/NCT01714739 NLM identifier: NCT01714739Accessed December 11, 2013
- ClinicalTrialsgov [homepage on the Internet]US National Institutes of Health Updated 2013 Available from: http://clinicaltrials.gov/Accessed October 8, 2013
- WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
- PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
- HerbstRSGordonMSFineGDA study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumorsJ Clin Oncol201331Suppl Abstr 3000
- WeberJSKählerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumabJ Clin Oncol201230212691269722614989
- WeberJReview: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse eventsOncologist200712786487217673617